Acquisition of SK Pharmaceutical for the first time in Korea

[아시아경제 박병희 기자] SK Corp. fulfilled its dream of becoming a global pharmaceutical company (FIPCO) like Pfizer in the United States by acquiring for the first time a US pharmaceutical company in Korea. (19659004)

SK Corp. decided to acquire a 100% stake in AMPAC Fine Chemicals, Inc. (CDMO), AMPAC Fine Chemicals (M) We plan to invest money.

Founded in California in the 1990s, the company produces pharmaceutical products for cancer drugs, central nervous system and cardiovascular treatments, the largest investment ever made by a Korean company in the acquisition and distribution of drugs. merger of foreign pharmaceutical companies. It is the largest raw material drug manufacturing company with a high growth rate of more than 15% per year. It has three production sites and a research center in the United States and employs more than 500 skilled employees.

SK Corporation acquired the Irish pharmaceutical plant in Europe last year and advanced to the United States, the world's largest market and to become the world's largest CDMO company.

SK Biotech, a wholly-owned subsidiary of SK Corporation, has been producing high value-added medicines since 1998 and exporting them to global pharmaceutical companies. Last year, SK Biotech was the first Korean company to acquire the Bristol Meersstee (BMS). With SK Biotech, SK Corporation currently produces 400,000 ℓ of raw materials in Korea and Ireland. MPAC's production capacity is 600,000 liters and the annual production capacity is 1 million liters. SK Corp. announced its intention to increase its annual production capacity to 1.6 million liters, the largest in the world, increasing until 2020. According to the plan, the company will take the lead in the world. the global CDMO industry, the world's largest country, with a total of 1.55 million liters.

Jang Dong-hyun, president of SK Corporation, said: "Bio-Pharma is one of the main growth drivers of SK Corp. and the acquisition of the MPP is a global business. [19659004] Meanwhile, SK Corp., another wholly-owned subsidiary of SK Corp., has entered the Global Clinical Phase 3 of Cenobamate, a patented brain tumor treatment product, with the US Food and Drug Administration (US). FDA) seeks approval for new drugs SK BioPharma is the first company in Korea to have completed the third phase of global clinical trials

In addition to biopharmaceuticals and pharmaceuticals, SK Chemicals is actively engaged in three major activities: shale energy and vehicle sharing services .. A representative of SK Corporation said: "We invested 1.5 trillion won last year and we plan to do it again. ; inv to be at least 1.5 trillion won this year. "

Park Byunghee reporter [email protected]